Jazz Pharmaceuticals plc (JAZZ) reported top-line results from the Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).
Jazz's Zepzelca Falls Short In Second-Line SCLC Trial
